Enfamil Growth Drives Mead Johnson Nutritionals During Strong BMS Quarter
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb's Mead Johnson Nutritionals division fared well in the first quarter, driven by a 26% increase in sales of Enfamil infant formula to $208 mil
You may also be interested in...
Will Pravachol Follow Zocor On UK Switch Route?
Mounting pressure on Pravachol revenues in 2004 due to the loss of patent exclusivity in Europe and an increasingly competitive U.S. landscape could prompt Bristol-Myers Squibb to intensify efforts to gain nonprescription status for the drug in both markets
Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC